This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) revealed that the U.S. Food and Drug Administration (FDA) has closed out its 'Warning Letter' related to the company's Zhejiang, China manufacturing facility.
Becton (BDX) with FlowJo to Provide Cloud Platform Services
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has entered into an agreement with FlowJo, LLC.
Mead Johnson-Reckitt Move to Merge, Deal Closes on Jun 15
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) and Reckitt Benckiser have cleared the final regulatory hurdle of their impending merger.
PetMed Express' New Order Sales Increase, Competition Rife
by Zacks Equity Research
On Jun 12, we issued an updated research report on Pompano Beach, FL-based PetMed Express, Inc. (PETS).
Quest Diagnostics to Buy 2 Labs, Grow in Oncology Space
by Zacks Equity Research
Quest Diagnostics (DGX) recently announced agreements to acquire two laboratory businesses in Lewisville, Texas, namely Med Fusion and Clear Point.
Phibro Animal Health (PAHC) Rides High on Solid Prospects
by Zacks Equity Research
On Jun 12, we issued an updated research report on NJ-based Phibro Animal Health Corporation (PAHC) ??? a leading global diversified animal health and mineral nutrition company.
Luminex's (LMNX) VERIGENE Panels Receive Approval in Japan
by Zacks Equity Research
Luminex Corporation (LMNX) recently announced that Japan's Central Social Insurance Medical Council has approved to provide reimbursement for VERIGENE assays.
Inogen (INGN) Up 8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Will Walgreens-Rite Aid Deal Fall Flat on FTC Blockade?
by Zacks Equity Research
Walgreens Boots Alliance, Inc. (WBA) stock took a marginal hit of 0.6% on Friday's close, following the news breakout that the FTC is blocking the impending Rite Aid merger deal.
Masimo (MASI) Presents Utility Study of Oxygen Reserve Index
by Zacks Equity Research
Masimo Corporation (MASI) recently announced data from its study evaluating the potential clinical utility of Masimo Oxygen Reserve Index.
NuVasive (NUVA) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of NuVasive, Inc. (NUVA) scaled a new 52-week high of $81.06 on Jun 9, eventually closing a bit lower at $79.13.
Cardiovascular Systems (CSII) Hits 52-Week High on Solid Q3
by Zacks Equity Research
Share price of Cardiovascular Systems, Inc. (CSII) scaled a new 52-week high of $32.68 on Jun 9, eventually closing a bit lower at $30.93.
EDAP TMS (EDAP) Shows Strength: Stock Adds 5.9% in Session
by Zacks Equity Research
EDAP TMS S.A. (EDAP) moved big last session, as its shares jumped almost 6% on the day.
Medtronic Launches MiniMed 670G to Better Manage Diabetes
by Zacks Equity Research
Medtronic plc (MDT) commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients.
Invacare (IVC) Prices $105 Million Convertible Senior Notes
by Zacks Equity Research
Invacare Corporation (IVC) recently announced that it has priced convertible senior notes worth $105 million.
CVS Health Gains on Pharmacy Services, Strategic Buyouts
by Zacks Equity Research
On Jun 8, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
Hologic Wins FDA Approval for Genius 3D Mammography Exam
by Zacks Equity Research
Hologic, Inc. (HOLX) continues to expand its Breast and Skeletal Health business through innovation and product development.
Zimmer Biomet Rides on Spine Business, Knee Challenges Stay
by Zacks Equity Research
On Jun 6, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).
Bruker Grows on NMR & Nano Businesses amid Several Odds
by Zacks Equity Research
On Jun 6, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR), a manufacturer of proprietary life science and materials research systems.
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)
by Zacks Equity Research
Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.
Cardiovascular Systems Innovation On Track, Competition Rife
by Zacks Equity Research
On Jun 6, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Here's Why You Should Bet on Humana (HUM) Stock Right Now
by Zacks Equity Research
Louisville-based Humana Inc. (HUM), one of the largest health care plan providers in the United States, has been an investor favorite, given its strong fundamentals
Medtronic SureTune3 Obtains Health Canada License for DBS
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of Health Canada license for SureTune 3 software for deep brain stimulation (DBS).
Boston Scientific Wins CE Mark for Vercise Gevia DBS System
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.
HealthEquity (HQY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity Inc (HQY) reported earnings of 19 cents per share in the first quarter of fiscal 2018, higher than the Zacks Consensus Estimate of 16 cents.